Mizuho Initiates Coverage on GoodRx (NASDAQ:GDRX)

Mizuho initiated coverage on shares of GoodRx (NASDAQ:GDRX) in a report released on Wednesday, MarketBeat Ratings reports. The firm set a “neutral” rating and a $5.00 price target on the stock. Mizuho’s price objective suggests a potential upside of 2.04% from the stock’s previous close.

GDRX has been the topic of several other research reports. Citigroup cut their price objective on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research note on Friday, August 9th. UBS Group dropped their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. Finally, Barclays reduced their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.60.

GoodRx Price Performance

GDRX stock opened at $4.90 on Wednesday. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock’s 50 day moving average is $5.83 and its two-hundred day moving average is $7.18. The company has a market capitalization of $1.87 billion, a PE ratio of -163.33, a P/E/G ratio of 3.58 and a beta of 1.29. GoodRx has a 52-week low of $4.09 and a 52-week high of $9.26.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GDRX. Cornercap Investment Counsel Inc. lifted its holdings in GoodRx by 1.7% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after acquiring an additional 1,266 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after purchasing an additional 3,444 shares in the last quarter. nVerses Capital LLC acquired a new stake in GoodRx during the third quarter valued at approximately $33,000. Plato Investment Management Ltd bought a new stake in GoodRx during the second quarter worth approximately $43,000. Finally, XTX Topco Ltd grew its position in GoodRx by 42.4% in the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after buying an additional 8,801 shares during the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.